“We are incredibly honored to have been able to attract people of this caliber to serve in an advisory capacity,” said Paul J. Fitzpatrick, CEO of ACT. “Bringing together these thought leaders will have a profound impact on ACT’s ability to develop catheter-based medical devices that improve endovascular procedures. We look forward to their guidance and experience to help accelerate our innovative devices so they can begin to benefit prospective patients as soon as possible.”
ACT’s lead product is the patented Occlusion Perfusion Catheter (OPC), a multi-lumen balloon catheter designed to temporarily occlude a specific region from blood flow to allow the local delivery of therapeutic agents to the peripheral and eventually the coronary vasculature. The OPC has the ability to create a localized treatment chamber for the delivery of various types of therapeutic agents, including pharmaceuticals, live cells and biologics, to treat a variety of disease states and place the agent circumferentially into the vasculature of the treatment chamber.
The members of the ACT Scientific Advisory Board are:
Dr. Bunch graduated from Meharry Medical College in 1987 and completed a residency in Internal Medicine at the University of the South Alabama Medical Center in 1992. He was Chief Resident in his senior year. He completed a fellowship in cardiology at Alton Oschner Medical Foundation from 1992-1995. He continued there as a fellow in interventional cardiology from 1995-1996.
In 1992 he received the P.D. McGehee Award for Scientific Writing. He has many publications and presentations and is on the Editorial Advisory Board of Cardiac Interventions Today. He has been a principal investigator for over 20 clinical investigational research studies.
Dr. Krebs graduated Doctor of Medicine from Texas A&M in 1981. He did a residency in diagnostic radiology at the University of Texas-San Antonio from 1981-1985, serving as chief resident in his senior year. He did a fellowship in angiography and interventional radiology from 1985-1986 at Emory University Hospital. He is board certified and a member of multiple medical societies.
Dr. Yazdani is currently an Assistant Professor in the Department of Mechanical Engineering at the University of South Alabama. He performed his postdoctoral training at CVPath Institute, evaluating the safety and efficacy of cardiovascular devices using pre-clinical and bench-top models. Dr. Yazdani obtained a Ph.D. in Biomedical Engineering from Wake Forest University, where he developed tissue engineered blood vessels. He has undergraduate and Master’s degrees from Virginia Tech in Engineering Science and Mechanics. Dr. Yazdani has published over 80 peer-reviewed journal papers, book chapters and conference abstracts.
Dr. Teeslink began his practice in 1968 as Chief of Vascular and Interventional Radiology at the Medical College of Georgia, the Veterans Administration and three private hospitals in Augusta, Georgia. He served in this capacity for 30 years, and continues his medical practice through medical consulting companies.
Dr. Teeslink has been actively involved throughout his career in leading-edge technology and continues to assist in the design, development and implementation of numerous medical devices and X-ray equipment. Dr. Teeslink has served as medical director and consultant for several companies. He has been instrumental in helping develop many of the interventional procedures that are utilized today. Dr. Teeslink has always been involved in medical education endeavors, including training medical students, residents, fellows and post graduate physicians. A recognized expert in his field, he has shared his knowledge and experience at numerous medical conferences, both nationally and internationally.